Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer

NCT06871527 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Gastric (Stomach) Cancer
Gastric Adenocarcinoma
Fruquintinib
PD-1 Inhibitor
Tislelizumab
GEJ Adenocarcinoma

Interventions

DRUG: fruquintinib + tislelizumab + FOLFOX

Sponsor

Sixth Affiliated Hospital, Sun Yat-sen University